基于数据挖掘与网络药理学技术的中药治疗非增殖期糖尿病视网膜病变经验总结

doi:10.20047/j.issn1673-7210.2022.36.04

Abstract
Figure/Table
References (30)
Related Citation (15)

Download: PDF (3264 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To summarize the experience of traditional Chinese medicine in treating non-proliferative diabetic retinopathy (NPDR) based on data mining and network pharmacology. Methods Literatures of treating NPDR with traditional Chinese medicine from CNKI and Wanfang Data were searched and collated, and the limited time was from inception to December 2020. Traditional Chinese medicine inheritance computing platform V 3.0 was used to build a prescription database, and the frequency, flavor, meridian transformation, and efficacy of related prescriptions were counted. Association rules of related drug pairs were analyzed, and medication rules and core compatibility of traditional Chinese medicine treatment of NPDR were summarized. For the core drug pairs, the traditional Chinese medicine systems pharmacology database and analysis platform, traditional Chinese medicine integrative database, Uniprot, and GeneCards were used to construct the “ingredient-target” network, and the protein-protein interaction network was constructed with STRING database and Cytoscape software, and molecular docking was carried out. GO classification enrichment analysis and KEGG pathway enrichment analysis were performed by R language. Results According to the analysis of 107 prescriptions of NPDR treated by traditional Chinese medicine, ten drugs were commonly used, among which Radix Astragali seu Hedysari, Radix Rehmanniae Recens, and Radix Notoginseng were the most frequently used. The four nature of drugs were mainly cold, flat, and warm, the five flavours were mainly bitter and sweet, the channel tropism were mainly liver, lung, and kidney channel. There were seven drug pairs with high frequency of use, among which Radix Astragali seu Hedysari-Radix Rehmanniae Recens, Radix Astragali seu Hedysari-Radix Notoginseng, and Radix Astragali seu Hedysari- Radix Notoginseng ranked the top three. Network pharmacological analysis of the Radix Astragali seu Hedysari-Radix Rehmanniae Recens drug pair showed that the main components included quercetin, kaempferol, formononetin, isorhamnetin, etc., and the main targets included TP53, SERPINE1, VEGFA, TNF, etc. KEGG and GO enrichment pathways showed that the active components of traditional Chinese medicine were related to cell proliferation, cell response to chemical stress, and cell response to lipopolysaccharide. The free energy calculation of core target protein and core active ingredient showed that the core active ingredient in Radix Astragali seu Hedysari-Radix Rehmanniae Recens drug pair (quercetin, kaempferol) had a good binding effect with the key core target in NPDR. Conclusion Radix Astragali seu Hedysari-Radix Rehmanniae Recens is a high-frequency drug for NPDR treatment in traditional Chinese medicine. Its components may play a regulatory role on multiple pathways by acting on multiple targets, which can provide guidance for clinical and basic research.

Key words： Non-proliferative diabetic retinopathy Data mining Network pharmacology Molecular docking technology

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Xiaocui1 YANG Zhihua2 XIE Yiqiang3 LI Rui4 CHENG Yawei5

Cite this article:

WU Xiaocui1 YANG Zhihua2 XIE Yiqiang3 LI Rui4 CHENG Yawei5. Summary of experience in treating non-proliferative diabetic retinopathy with traditional Chinese medicine based on data mining and network pharmacology[J]. 中国医药导报, 2022, 19(36): 21-28.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2022.36.04 OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I36/21

[1] Vujosevic S，Aldington SJ，Silva P，et al. Screening for diabetic retinopathy：new perspectives and challenges [J]. Lancet Diabetes Endocrinol，2020，8（4）：337-347.
[2] Rohm TV，Meier DT，Olefsky JM，et al. Inflammation in obesity，diabetes，and related disorders [J]. Immunity，2022，55（1）：31-55.
[3] Kang Q，Yang C. Oxidative stress and diabetic retinopathy：Molecular mechanisms，pathogenetic role and therapeutic implications [J]. Redox Biology，2020，37：101799.
[4] Homme RP，Singh M，Majumder A，et al. Remodeling of Retinal Architecture in Diabetic Retinopathy：Disruption of Ocular Physiology and Visual Functions by Inflammatory Gene Products and Pyroptosis [J]. Front Physiol，2018，9：1268.
[5] 何媛，周涛，苏婷，等.糖尿病视网膜病变的分类、发生机制及治疗进展[J].山东医药，2020，60（19）：111-115.
[6] 郑通美.眼底激光联合康柏西普治疗糖尿病视网膜病变效果分析[J].中国医药科学，2021，11（6）：215-217，228.
[7] 潘毅溢，谢倩，曹菲，等.眼底激光配合羟苯磺酸钙胶囊口服治疗在糖尿病性视网膜病变患者中的应用效果[J].中国当代医药，2022，29（12）：99-102.
[8] 孙河，杨稀瑞，董霏雪，等.基于网络药理学分析达明饮治疗糖尿病视网膜病变的作用机制研究[J].中国中医眼科杂志，2020，30（11）：829-836.
[9] 余积洁，康斌，万金兰.活血明目汤导入治疗非增殖性糖尿病视网膜病变的临床效果[J].中国当代医药，2021，28（5）：148-150，154.
[10] 高学敏.中药学[M].北京：中国中医药出版社，2002.
[11] 国家药典委员会.中华人民共和国药典[S].一部.北京：中国医药科技出版社，2015.
[12] 王云丹，张依倩，郝磊，等.芪苓温肾消囊方化学成分及其治疗多囊卵巢综合征的作用机制分析[J].中国实验方剂学杂志，2022，28（8）：183-193.
[13] 姜小帆，邵明义，蔡东梅，等.糖尿病视网膜病变辨证分型及证候要素分布的文献研究[J].时珍国医国药，2009， 20（12）：3171-3173.
[14] 冉德聪，张忠勇，王晓蕴，等.中医防治糖尿病视网膜病变的研究进展[J].河北中医药学报，2022，37（1）：57-60， 64.
[15] 查宝丽，刘昳.糖尿病视网膜病变中西医治疗研究进展[J].辽宁中医药大学学报，2020，22（4）：153-157.
[16] 马英琦，黄延芹，徐云生.中医治疗非增殖期糖尿病视网膜病变研究进展[J].河北中医，2019，41（5）：779-782.
[17] 宋其蔓，徐新禹，徐林松.槲皮素减轻高糖条件下人肾小球内皮细胞损伤的实验研究[J].临床和实验医学杂志，2020，19（3）：256-260.
[18] 陈丽华，凌梓韵，李霭燕，等.通络明目膏对糖尿病视网膜病变大鼠微血管的保护作用及其作用机制研究[J].中国医药科学，2022，12（17）：30-34.
[19] 李小珩，李蓉，朱巧平.槲皮素对高糖诱导的脉络膜和视网膜细胞血管生成的影响及其与细胞自噬的关系[J].山西医科大学学报，2019，50（12）：1732-1737.
[20] 杨胜楠.山奈酚-3-O-葡萄糖醛酸苷、黄芩苷调节糖代谢的作用机制研究[D].天津：南开大学，2019.
[21] 徐晓红.山奈酚对糖尿病视网膜病变中VEGF和PGF作用机制研究[D].南京：南京医科大学，2018.
[22] Wu J，Ke X，Ma N，et al. Formononetin，an active compound of Astragalus membranaceus（Fisch）Bunge，inhibits hypoxia- induced retinal neovascularization via the HIF-1α/ VEGF signaling pathway [J]. Drug Des Devel Ther，2016， 10：3071-3081.
[23] Li Y，Guo S，Zhu Y，et al. Flowers of Astragalus membranaceus var. mongholicus as a Novel High Potential By-Product: Phytochemical Characterization and Antioxidant Activity [J]. Molecules，2019，24（3）：434.
[24] Idriss HT，Naismith JH. TNF alpha and the TNF receptor superfamily：structure-function relationship（s）[J]. Microsc Res Tech，2000，50（3）：184-195.
[25] 程金涛，李曼，张庆芬，等.糖尿病视网膜病变与患者血清丝氨酸蛋白酶抑制剂、胰岛素抵抗及糖脂代谢相关性的研究[J].中华眼科医学杂志（电子版），2017，7（3）：103-108.
[26] Karaman S，Lepp?覿nen VM，Alitalo K. Vascular endothelial growth factor signaling in development and disease [J]. Development，2018，145（14）：dev151019.
[27] Liu J，Guan D，Dong M，et al. UFMylation maintains tumour suppressor p53 stability by antagonizing its ubiquitination [J]. Nat Cell Biol，2020，22（9）：1056-1063.
[28] Lin YC，Shen ZR，Song XH，et al. Comparative transcriptomic analysis reveals adriamycin-induced apoptosis via p53 signaling pathway in retinal pigment epithelial cells [J]. J Zhejiang Univ Sci B，2018，19（12）：895-909.
[29] Wang L，Ma T，Zheng Y，et al. Diosgenin inhibits IL-1β- induced expression of inflammatory mediators in human osteoarthritis chondrocytes [J]. Int J Clin Exp Pathol，2015，8（5）：4830-4836.
[30] Wang JN，Yang Q，Yang C，et al. Smad3 promotes AKI sensitivity in diabetic mice via interaction with p53 and induction of NOX4-dependent ROS production [J]. Redox Biology，2020，32：101479.